AR037680A1 - Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d - Google Patents
Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades dInfo
- Publication number
- AR037680A1 AR037680A1 ARP020104561A ARP020104561A AR037680A1 AR 037680 A1 AR037680 A1 AR 037680A1 AR P020104561 A ARP020104561 A AR P020104561A AR P020104561 A ARP020104561 A AR P020104561A AR 037680 A1 AR037680 A1 AR 037680A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- amino
- substituents
- aryl
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- 125000004442 acylamino group Chemical group 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003725 azepanyl group Chemical group 0.000 abstract 4
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003386 piperidinyl group Chemical group 0.000 abstract 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 2
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003230 pyrimidines Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
5-amino-pirazolo-[4,3-e]-1.2,4-triazolo[1,5-c]pirimidinas sustituidas que tienen la fórmula estructural (1) o una sal o solvato farmacéuticamente aceptable de dicho compuesto, en el cual: R es seleccionado entre el grupo que consiste en R1-furanilo-, R1 tienilo, R1-piridilo-, R1-oxazolilo, R1-pirrolilo- y R2-arilo; X es -(CH2)n-, Y es un grupo piperidinilo, pirrolidinilo o azepanilo con una porción arilo o heteroarilo fusionada a dos átomos de carbono adyacentes en Y, donde X está unido al átomo de N del grupo piperidinilo, pirrolidinilo o azepanilo: Q representa 1-4 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, cicloalquilo, cicloheteroalquilo, amino, arilo, aralquilo, heteroarilo, alquilo, CF3, CN, halógeno, NO2, alcoxi, alcoxialcoxi, cicloalquilalcoxi, aciloxi, alquilamino, acilamino, alquilsulfonamino, alquilaminosulfonilo, dialquilaminosulfonilo, NH2SO2- e hidroxi; n es 1 a 4; R1 es 1-3 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, alquilo, CF3, halógeno y NO2 y R2 representa 1-3 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, alquilo, CF3, halógeno, NO2, alcoxi, aciloxi, alquilamino, acilamino, alquilsulfonamido, alquilaminosulfonilo, dialquilaminosulfonilo e hidroxilo; composiciones farmacéuticas que los comprenden, el uso de dichos compuestos, solos o en combinación para la elaboración de un medicamento útiles para el tratamiento de enfermedades del sistema nervioso central, en especial el tratamiento del Parkinson y un kit. 5-amino-pirazolo-[4,3-e]-1.2,4-triazolo[1,5-c]pirimidinas sustituidas que tienen la fórmula estructural (1) o una sal o solvato farmacéuticamente aceptable de dicho compuesto, en el cual: R es seleccionado entre el grupo que consiste en R1-furanilo-, R1 tienilo, R1-piridilo-, R1-oxazolilo, R1-pirrolilo- y R2-arilo; X es -(CH2)n-, Y es un grupo piperidinilo o azepanilo con una porción arilo o heteroarilo fusionada a dos átomos de carbono adyacentes en Y, donde X está unido al átomo de N del grupo piperidinilo, pirrolidinilo o azepanilo: Q representa 1-4 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, cicloalquilo, cicloheteroalquilo, amino, arilo, aralquilo, heteroarilo, alquilo, CF3, CN, halógeno, NO2, alcoxi, alcoxialcoxi, cicloalquilalcoxi, aciloxi, alquilamino, acilamino, alquilsulfonamino, alquilaminosulfonilo, dialquilaminosulfonilo, NH2SO2- e hidroxi; n es 1 a 4; R1 es 1-3 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, alquilo, CF3, halógeno y NO2 y R2 representa 1-3 sustituyentes, que pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en hidrógeno, alquilo, CF3, halógeno, NO2, alcoxi, aciloxi, alquilamino, acilamino, alquilsulfonamido, alquilaminosulfonilo, dialquilaminosulfonilo e hidroxilo; composiciones farmacéuticas que los comprenden, el uso de dichos compuestos, solos o en combinación para la elaboración de un medicamento útiles para el tratamiento de enfermedades del sistema nervioso central, en especial el tratamiento del Parkinson y un kit.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33434201P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037680A1 true AR037680A1 (es) | 2004-12-01 |
Family
ID=23306779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104561A AR037680A1 (es) | 2001-11-30 | 2002-11-27 | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6916811B2 (es) |
| EP (1) | EP1448565B1 (es) |
| JP (2) | JP4284182B2 (es) |
| KR (1) | KR20050044593A (es) |
| CN (1) | CN1692116A (es) |
| AR (1) | AR037680A1 (es) |
| AT (1) | ATE453647T1 (es) |
| AU (1) | AU2002346503A1 (es) |
| CA (1) | CA2468649C (es) |
| DE (1) | DE60234951D1 (es) |
| ES (1) | ES2336435T3 (es) |
| HU (1) | HUP0402018A3 (es) |
| IL (1) | IL161716A0 (es) |
| MX (1) | MXPA04005209A (es) |
| PE (1) | PE20030665A1 (es) |
| TW (1) | TW200306837A (es) |
| WO (1) | WO2003048165A1 (es) |
| ZA (1) | ZA200404161B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287748B6 (sk) * | 2000-05-26 | 2011-08-04 | Schering Corporation | Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6964288B2 (en) * | 2001-07-06 | 2005-11-15 | Ksaria Corporation | Apparatus and method for automated preparation of an optical fiber |
| EP1435960B1 (en) | 2001-10-15 | 2014-07-30 | Merck Sharp & Dohme Corp. | Imidazo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as adenosine a2a receptor antagonists |
| WO2003101455A2 (en) * | 2002-05-30 | 2003-12-11 | King Pharmaceuticals Research & Development, Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| NZ540493A (en) | 2002-12-19 | 2008-04-30 | Schering Corp | Uses of adenosine A2a receptor antagonists |
| JP4800216B2 (ja) * | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| DK1678182T3 (da) * | 2003-10-28 | 2007-06-04 | Schering Corp | Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner |
| US20060009504A1 (en) * | 2003-12-19 | 2006-01-12 | Schering Corporation | Pharmaceutical compositions |
| WO2006132275A1 (ja) * | 2005-06-07 | 2006-12-14 | Kyowa Hakko Kogyo Co., Ltd. | 運動障害の予防および／または治療剤 |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| US8338421B2 (en) | 2008-08-01 | 2012-12-25 | Alpha Synergy Development, Inc. | Compositions and methods for reversing rebound hyperemia |
| US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
| US12246013B2 (en) | 2008-08-01 | 2025-03-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| WO2010078430A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| TW201100427A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted heterocyclic compounds |
| US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
| US20110152271A1 (en) * | 2009-12-17 | 2011-06-23 | Gerald Horn | Compositions and methods for ophthalmic delivery of nasal decongestants |
| US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
| US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
| CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
| WO2020106558A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP2022511778A (ja) | 2018-11-30 | 2022-02-01 | メルク・シャープ・アンド・ドーム・コーポレーション | アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
| JOP20210116A1 (ar) | 2018-11-30 | 2023-01-30 | Merck Sharp & Dohme | مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها |
| DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
| US20230024108A1 (en) * | 2019-07-17 | 2023-01-26 | Teon Therapeutics, Inc. | Adenosine a2a receptor antagonists |
| CN112608316B (zh) | 2019-07-30 | 2022-10-21 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类腺苷受体拮抗剂 |
| CN112625050B (zh) | 2019-07-30 | 2021-10-01 | 杭州阿诺生物医药科技有限公司 | 一种a2a和/或a2b受体抑制剂的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| ATE208199T1 (de) | 1993-07-27 | 2001-11-15 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen parkinsonsche krankheit |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6921825B2 (en) * | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| SK287748B6 (sk) * | 2000-05-26 | 2011-08-04 | Schering Corporation | Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| WO2003101455A2 (en) * | 2002-05-30 | 2003-12-11 | King Pharmaceuticals Research & Development, Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| TWI355381B (en) * | 2003-04-23 | 2012-01-01 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri |
-
2002
- 2002-11-26 JP JP2003549355A patent/JP4284182B2/ja not_active Expired - Fee Related
- 2002-11-26 AT AT02784568T patent/ATE453647T1/de not_active IP Right Cessation
- 2002-11-26 IL IL16171602A patent/IL161716A0/xx unknown
- 2002-11-26 CN CNA02823782XA patent/CN1692116A/zh active Pending
- 2002-11-26 HU HU0402018A patent/HUP0402018A3/hu unknown
- 2002-11-26 DE DE60234951T patent/DE60234951D1/de not_active Expired - Lifetime
- 2002-11-26 ES ES02784568T patent/ES2336435T3/es not_active Expired - Lifetime
- 2002-11-26 CA CA002468649A patent/CA2468649C/en not_active Expired - Fee Related
- 2002-11-26 EP EP02784568A patent/EP1448565B1/en not_active Expired - Lifetime
- 2002-11-26 MX MXPA04005209A patent/MXPA04005209A/es active IP Right Grant
- 2002-11-26 US US10/304,931 patent/US6916811B2/en not_active Expired - Lifetime
- 2002-11-26 KR KR1020047007876A patent/KR20050044593A/ko not_active Withdrawn
- 2002-11-26 WO PCT/US2002/037710 patent/WO2003048165A1/en not_active Ceased
- 2002-11-26 AU AU2002346503A patent/AU2002346503A1/en not_active Abandoned
- 2002-11-27 PE PE2002001143A patent/PE20030665A1/es not_active Application Discontinuation
- 2002-11-27 TW TW091134471A patent/TW200306837A/zh unknown
- 2002-11-27 AR ARP020104561A patent/AR037680A1/es unknown
-
2004
- 2004-05-27 ZA ZA200404161A patent/ZA200404161B/en unknown
-
2008
- 2008-06-04 JP JP2008147306A patent/JP2008260776A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20030212059A1 (en) | 2003-11-13 |
| WO2003048165A1 (en) | 2003-06-12 |
| EP1448565B1 (en) | 2009-12-30 |
| KR20050044593A (ko) | 2005-05-12 |
| HUP0402018A3 (en) | 2008-06-30 |
| JP2005511699A (ja) | 2005-04-28 |
| ES2336435T3 (es) | 2010-04-13 |
| HK1063780A1 (en) | 2005-01-14 |
| MXPA04005209A (es) | 2004-08-19 |
| US6916811B2 (en) | 2005-07-12 |
| TW200306837A (en) | 2003-12-01 |
| CA2468649A1 (en) | 2003-06-12 |
| IL161716A0 (en) | 2004-09-27 |
| JP2008260776A (ja) | 2008-10-30 |
| PE20030665A1 (es) | 2003-08-08 |
| JP4284182B2 (ja) | 2009-06-24 |
| AU2002346503A1 (en) | 2003-06-17 |
| EP1448565A1 (en) | 2004-08-25 |
| DE60234951D1 (de) | 2010-02-11 |
| ATE453647T1 (de) | 2010-01-15 |
| CA2468649C (en) | 2009-03-10 |
| HUP0402018A2 (hu) | 2005-02-28 |
| ZA200404161B (en) | 2005-11-30 |
| CN1692116A (zh) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| AR037243A1 (es) | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| AR037731A1 (es) | Uso de ureas de benzotiazoles | |
| JP2006505581A5 (es) | ||
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| EA200201291A1 (ru) | Производные пурина | |
| EA200101203A1 (ru) | Производные пурина | |
| KR950704320A (ko) | Crf 길항제로서의 피롤로피리미딘(pyrrolopyrimidines as crf antagonists) | |
| AR086528A2 (es) | Combinacion farmaceutica | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| RU2008126807A (ru) | Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов | |
| AR037681A1 (es) | Antagonistas receptores de adenosina a2a de 5-amino-[1,2,4]-triazol biciclico, composiciones farmaceuticas que los comprenden, el uso de las mismas, solo o en combinacion de los compuestos y otros agentes para la preparacion de medicamentos utiles en el tratamiento de la enfermedad de parkinson y un | |
| ES2701087T3 (es) | Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis | |
| US20220202814A1 (en) | Treatment of cancer | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| WO2021003417A1 (en) | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof | |
| PE20050711A1 (es) | Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina | |
| TW200745130A (en) | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | |
| AR046967A1 (es) | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| EA200700144A1 (ru) | Производные пиридопиримидина, их получение, их применение в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |